nach oben

International Urology and Nephrology

Erschienen in:

16.12.2016 | Urology - Review

The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside

verfasst von: Jieping Hu, Qingke Chen

Erschienen in: International Urology and Nephrology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Glucocorticoids are a common class of adjuvant drugs for the treatment of castration-resistant prostate cancer (CRPC) combined with antitumour or antiandrogen agents. Glucocorticoids are administered clinically because they ameliorate toxic side effects and have inhibitory effects on adrenal androgen production, acting as a pituitary suppressant. However, their effects on prostate cancer cells especially the castration resistance prostate cancer cells are poorly defined. Glucocorticoids exert effects depend to a great extent on glucocorticoid receptor. In addition to a number of glucocorticoid receptor isoforms determined, it is found that the actions of glucocorticoids through GRα are influenced by other isoforms, such as GRβ and GRγ. Recently, studies found GR confers resistance to androgen deprivation therapy, and various glucocorticoids exert distinct efficacy in CRPC. In this review, we summarized the mechanisms of glucocorticoids and its clinical appliances on the basis of present evidence.

Sharifi N (2014) Steroid receptors aplenty in prostate cancer. New Engl J Med 370(10):970–971. doi:10.1056/NEJMcibr1315706 PubMedCrossRef

Valenca LB, Sweeney CJ, Pomerantz MM (2015) Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treat Rev 41(4):332–340. doi:10.1016/j.ctrv.2015.02.010 PubMedCrossRef

Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB (2015) Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 67(3):470–479. doi:10.1016/j.eururo.2014.09.049 PubMedCrossRef

Wadosky KM, Koochekpour S (2016) Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget. doi:10.18632/oncotarget.10901 PubMed

Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701–711. doi:10.1038/nrc4016 PubMedPubMedCentralCrossRef

Chatzopoulou A, Roy U, Meijer AH, Alia A, Spaink HP, Schaaf MJ (2015) Transcriptional and metabolic effects of glucocorticoid receptor alpha and beta signaling in zebrafish. Endocrinology:en20141941. doi:10.1210/en.2014-1941

Yemelyanov A, Czwornog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X, Budunova I (2007) Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26(13):1885–1896. doi:10.1038/sj.onc.1209991 PubMedCrossRef

Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, Zheng D, Sawyers CL (2013) Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155(6):1309–1322. doi:10.1016/j.cell.2013.11.012 PubMedPubMedCentralCrossRef

Matthews LC, Berry AA, Morgan DJ, Poolman TM, Bauer K, Kramer F, Spiller DG, Richardson RV, Chapman KE, Farrow SN, Norman MR, Williamson AJ, Whetton AD, Taylor SS, Tuckermann JP, White MR, Ray DW (2015) Glucocorticoid receptor regulates accurate chromosome segregation and is associated with malignancy. Proc Natl Acad Sci USA. doi:10.1073/pnas.1411356112

10.

Xie N, Cheng H, Lin D, Liu L, Yang O, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P, Dong X (2015) The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer J Int Du Cancer 136(4):E27–E38. doi:10.1002/ijc.29147 CrossRef

11.

Oakley RH, Cidlowski JA (2013) The biology of the glucocorticoid receptor: new signaling mechanisms in health and disease. J Allergy Clin Immunol 132(5):1033–1044. doi:10.1016/j.jaci.2013.09.007 PubMedPubMedCentralCrossRef

12.

Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, Janne OA (2013) FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 73(5):1570–1580. doi:10.1158/0008-5472.can-12-2350 PubMedCrossRef

13.

Cleutjens CB, Steketee K, van Eekelen CC, van der Korput JA, Brinkmann AO, Trapman J (1997) Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology 138(12):5293–5300. doi:10.1210/endo.138.12.5564 PubMed

14.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE, Investigators C-A- (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368(2):138–148. doi:10.1056/NEJMoa1209096 PubMedCrossRef

15.

Kassi E, Moutsatsou P (2011) Glucocorticoid receptor signaling and prostate cancer. Cancer Lett 302(1):1–10. doi:10.1016/j.canlet.2010.10.020 PubMedCrossRef

16.

Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS (2014) Systemic therapy in men with metastatic castration-resistant prostate cancer: american society of clinical oncology and cancer care ontario clinical practice guideline. J Clin Oncol 32(30):3436–3448. doi:10.1200/JCO.2013.54.8404 PubMedPubMedCentralCrossRef

17.

De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, Investigators C-A- (2011) Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 364(21):1995–2005PubMedPubMedCentralCrossRef

18.

Khandwala HM, Vassilopoulou-Sellin R, Logethetis CJ, Friend KE (2001) Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer. Endocr Pract 7(1):11–15. doi:10.4158/EP.7.1.11 PubMedCrossRef

19.

Zheng Y, Izumi K, Li Y, Ishiguro H, Miyamoto H (2012) Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther 11(12):2621–2632. doi:10.1158/1535-7163.MCT-12-0621 PubMedCrossRef

20.

Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A (2001) Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93(22):1739–1746PubMedCrossRef

21.

Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ (2014) Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5(2):72–89. doi:10.1007/s12672-014-0173-2 PubMedPubMedCentralCrossRef

22.

Rane JK, Erb HH, Nappo G, Mann VM, Simms MS, Collins AT, Visakorpi T, Maitland NJ (2016) Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget. doi:10.18632/oncotarget.10207

23.

Kroon J, Puhr M, Buijs JT, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G (2016) Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer. Endocr Relat Cancer 23(1):35–45. doi:10.1530/ERC-15-0343 PubMedPubMedCentralCrossRef

24.

Sartor O, Weinberger M, Moore A, Li A, Figg WD (1998) Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology 52(2):252–256PubMedCrossRef

25.

Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A (2000) Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 89(12):2570–2576PubMedCrossRef

26.

Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL (1995) Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76(1):96–100PubMedCrossRef

27.

Fruchter O, Kino T, Zoumakis E, Alesci S, De Martino M, Chrousos G, Hochberg Z (2005) The human glucocorticoid receptor (GR) isoform beta differentially suppresses GR{alpha}-induced transactivation stimulated by synthetic glucocorticoids. J Clin Endocrinol Metab 90(6):3505–3509. doi:10.1210/jc.2004-1646 PubMedCrossRef

28.

Kino T, Su YA, Chrousos GP (2009) Human glucocorticoid receptor isoform beta: recent understanding of its potential implications in physiology and pathophysiology. Cell Mol Life Sci 66(21):3435–3448. doi:10.1007/s00018-009-0098-z PubMedPubMedCentralCrossRef

29.

Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, Consler TG, Parks DJ, Stewart EL, Willson TM, Lambert MH, Moore JT, Pearce KH, Xu HE (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110(1):93–105PubMedCrossRef

30.

Oakley RH, Sar M, Cidlowski JA (1996) The human glucocorticoid receptor beta isoform. Expression, biochemical properties, and putative function. J Biol Chem 271(16):9550–9559PubMedCrossRef

31.

Bamberger CM, Bamberger AM, de Castro M, Chrousos GP (1995) Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Investig 95(6):2435–2441. doi:10.1172/JCI117943 PubMedPubMedCentralCrossRef

32.

Gross KL, Lu NZ, Cidlowski JA (2009) Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 300(1–2):7–16. doi:10.1016/j.mce.2008.10.001 PubMedCrossRef

33.

Hollenberg SM, Weinberger C, Ong ES, Cerelli G, Oro A, Lebo R, Thompson EB, Rosenfeld MG, Evans RM (1985) Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318(6047):635–641PubMedCrossRef

34.

Kino T, Manoli I, Kelkar S, Wang YH, Su YA, Chrousos GP (2009) Glucocorticoid receptor (GR) beta has intrinsic, GR alpha-independent transcriptional activity. Biochem Biophys Res Commun 381(4):671–675. doi:10.1016/j.bbrc.2009.02.110 PubMedPubMedCentralCrossRef

35.

Stechschulte LA, Wuescher L, Marino JS, Hill JW, Eng C, Hinds TD Jr (2014) Glucocorticoid receptor beta stimulates Akt1 growth pathway by attenuation of PTEN. J Biol Chem 289(25):17885–17894. doi:10.1074/jbc.M113.544072 PubMedPubMedCentralCrossRef

36.

Lewis-Tuffin LJ, Jewell CM, Bienstock RJ, Collins JB, Cidlowski JA (2007) Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Mol Cell Biol 27(6):2266–2282. doi:10.1128/MCB.01439-06 PubMedPubMedCentralCrossRef

37.

Ligr M, Li Y, Logan SK, Taneja S, Melamed J, Lepor H, Garabedian MJ, Lee P (2012) Mifepristone inhibits GRbeta coupled prostate cancer cell proliferation. J Urol 188(3):981–988. doi:10.1016/j.juro.2012.04.102 PubMedPubMedCentralCrossRef

38.

El Etreby MF, Liang Y, Lewis RW (2000) Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 43(1):31–42PubMedCrossRef

39.

Song LN, Coghlan M, Gelmann EP (2004) Antiandrogen effects of mifepristone on coactivator and corepressor interactions with the androgen receptor. Mol Endocrinol (Baltimore, Md) 18(1):70–85. doi:10.1210/me.2003-0189 CrossRef

40.

Min KJ, Jang JH, Lee JT, Choi KS, Kwon TK (2012) Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2. J Mol Med 90(3):309–319. doi:10.1007/s00109-011-0821-8 PubMedCrossRef

41.

Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA (1999) The dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and mechanisms of action. J Biol Chem 274(39):27857–27866PubMedCrossRef

42.

Czock D, Keller F, Rasche FM, Haussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44(1):61–98. doi:10.2165/00003088-200544010-00003 PubMedCrossRef

43.

Mohler JL, Chen Y, Hamil K, Hall SH, Cidlowski JA, Wilson EM, French FS, Sar M (1996) Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res 2(5):889–895PubMed

44.

Zhao B, Choi JP, Jaehne M, Gao YR, Desai R, Tuckermann J, Zhou H, Handelsman DJ, Simanainen U (2014) Glucocorticoid receptor in prostate epithelia is not required for corticosteroid-induced epithelial hyperproliferation in the mouse prostate. Prostate 74(10):1068–1078. doi:10.1002/pros.22825 PubMedCrossRef

45.

Davies P, Rushmere NK (1990) Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements. J Mol Endocrinol 5(2):117–127PubMedCrossRef

46.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM (2016) BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer. Mol Cancer Res 14(4):324–331. doi:10.1158/1541-7786.MCR-15-0472 PubMedCrossRef

47.

Zhu J, Gong JY, Goodman OB Jr, Cartegni L, Nanus DM, Shen R (2007) Bombesin attenuates pre-mRNA splicing of glucocorticoid receptor by regulating the expression of serine-arginine protein p30c (SRp30c) in prostate cancer cells. Biochim Biophys Acta 1773(7):1087–1094. doi:10.1016/j.bbamcr.2007.04.016 PubMedPubMedCentralCrossRef

48.

Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S (2013) Glucocorticoid receptor-beta up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol 33(2):466–478. doi:10.1007/s10875-012-9828-3 PubMedCrossRef

49.

Li B, Bai X, Wanh H (2006) Effect of dexamethasone on expression of glucocorticoid receptor in human monocyte cell line THP-1. J Huazhong Univ Sci Technol Med Sci 26(1):25–27PubMedCrossRef

50.

Pinto A, Malacrida B, Oieni J, Serafini MM, Davin A, Galbiati V, Corsini E, Racchi M (2015) DHEA modulates the effect of cortisol on RACK1 expression via interference with the splicing of the glucocorticoid receptor. Br J Pharmacol. doi:10.1111/bph.13097

51.

Niu Y, Altuwaijri S, Yeh S, Lai KP, Yu S, Chuang KH, Huang SP, Lardy H, Chang C (2008) Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA 105(34):12188–12193. doi:10.1073/pnas.0804701105 PubMedPubMedCentralCrossRef

52.

Endo I, Mastumoto T (2014) Bone and Stem Cells. Regulatory mechanism of mesenchymal stem cell differentiation to osteoblasts. Clin Calcium 24 (4):555–564. doi:CliCa1404555564

53.

Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC (2005) Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 26(7):898–915. doi:10.1210/er.2003-0034 PubMedCrossRef

54.

Dolznig H, Grebien F, Deiner EM, Stangl K, Kolbus A, Habermann B, Kerenyi MA, Kieslinger M, Moriggl R, Beug H, Mullner EW (2006) Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. Oncogene 25(20):2890–2900. doi:10.1038/sj.onc.1209308 PubMedPubMedCentralCrossRef

55.

Varricchio L, Masselli E, Alfani E, Battistini A, Migliaccio G, Vannucchi AM, Zhang W, Rondelli D, Godbold J, Ghinassi B, Whitsett C, Hoffman R, Migliaccio AR (2011) The dominant negative beta isoform of the glucocorticoid receptor is uniquely expressed in erythroid cells expanded from polycythemia vera patients. Blood 118(2):425–436. doi:10.1182/blood-2010-07-296921 PubMedPubMedCentralCrossRef

56.

Danielpour D (1999) Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci 112(Pt 2):169–179PubMed

57.

Yano A, Fujii Y, Iwai A, Kageyama Y, Kihara K (2006) Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12(10):3003–3009. doi:10.1158/1078-0432.ccr-05-2085 PubMedCrossRef

58.

Drebert Z, Bracke M, Beck IM (2015) Glucocorticoids and the non-steroidal selective glucocorticoid receptor modulator, compound A, differentially affect colon cancer-derived myofibroblasts. J Steroid Biochem Mol Biol 149:92–105. doi:10.1016/j.jsbmb.2015.02.002 PubMedCrossRef

59.

Yan TZ, Jin FS, Xie LP, Li LC (2008) Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer. Urol Int 81(2):228–233. doi:10.1159/000144067 PubMedCrossRef

60.

Attardi BJ, Burgenson J, Hild SA, Reel JR (2004) Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol 222(1–2):121–132. doi:10.1016/j.mce.2004.04.013 PubMedCrossRef

61.

Montgomery B, Cheng HH, Drechsler J, Mostaghel EA (2014) Glucocorticoids and prostate cancer treatment: friend or foe? Asian J Androl 16(3):354–358. doi:10.4103/1008-682x.125392 PubMedPubMedCentralCrossRef

62.

Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, Koutsilieris M (1995) Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 26(5):260–269PubMedCrossRef

63.

Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM, Xu H (2008) Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression. Asian J Androl 10(4):635–641. doi:10.1111/j.1745-7262.2008.00352.x PubMedCrossRef

64.

Yudt MR, Jewell CM, Bienstock RJ, Cidlowski JA (2003) Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol 23(12):4319–4330PubMedPubMedCentralCrossRef

65.

Strickland I, Kisich K, Hauk PJ, Vottero A, Chrousos GP, Klemm DJ, Leung DYM (2001) High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids. J Exp Med 193(5):585–593. doi:10.1084/jem.193.5.585 PubMedPubMedCentralCrossRef

66.

Torrego A, Pujols L, Roca-Ferrer J, Mullol J, Xaubet A, Picado C (2004) Glucocorticoid receptor isoforms alpha and beta in in vitro cytokine-induced glucocorticoid insensitivity. Am J Respir Crit Care Med 170(4):420–425. doi:10.1164/rccm.200308-1143OC PubMedCrossRef

67.

Wang Q, Lu PH, Shi ZF, Xu YJ, Xiang J, Wang YX, Deng LX, Xie P, Yin Y, Zhang B, Mu HJ, Qiao WZ, Cui H, Zou J (2014) Glucocorticoid Receptor beta Acts as a Co-activator of T-Cell Factor 4 and Enhances Glioma Cell Proliferation. Mol Neurobiol. doi:10.1007/s12035-014-8900-9

68.

Beger C, Gerdes K, Lauten M, Tissing WJ, Fernandez-Munoz I, Schrappe M, Welte K (2003) Expression and structural analysis of glucocorticoid receptor isoform gamma in human leukaemia cells using an isoform-specific real-time polymerase chain reaction approach. Br J Haematol 122(2):245–252PubMedCrossRef

69.

Anbalagan M, Huderson B, Murphy L, Rowan BG (2012) Post-translational modifications of nuclear receptors and human disease. Nucl Recept Signal 10:e001. doi:10.1621/nrs.10001 PubMedPubMedCentral

70.

Jaaskelainen T, Makkonen H, Palvimo JJ (2011) Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 11(4):326–331. doi:10.1016/j.coph.2011.04.006 PubMedCrossRef

71.

Zhang X, Clark AF, Yorio T (2008) FK506-binding protein 51 regulates nuclear transport of the glucocorticoid receptor beta and glucocorticoid responsiveness. Invest Ophthalmol Vis Sci 49(3):1037–1047. doi:10.1167/iovs.07-1279 PubMedPubMedCentralCrossRef

72.

Narayanan S, Srinivas S, Feldman D (2016) Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol 13(1):47–60. doi:10.1038/nrurol.2015.254 PubMedCrossRef

73.

Haller J, Mikics E, Makara GB (2008) The effects of non-genomic glucocorticoid mechanisms on bodily functions and the central neural system. A critical evaluation of findings. Front Neuroendocrinol 29(2):273–291. doi:10.1016/j.yfrne.2007.10.004 PubMedCrossRef

74.

Lee SR, Kim HK, Song IS, Youm J, Dizon LA, Jeong SH, Ko TH, Heo HJ, Ko KS, Rhee BD, Kim N, Han J (2013) Glucocorticoids and their receptors: insights into specific roles in mitochondria. Prog Biophys Mol Bio 112(1–2):44–54. doi:10.1016/j.pbiomolbio.2013.04.001 CrossRef

75.

Talaber G, Boldizsar F, Bartis D, Palinkas L, Szabo M, Berta G, Setalo G Jr, Nemeth P, Berki T (2009) Mitochondrial translocation of the glucocorticoid receptor in double-positive thymocytes correlates with their sensitivity to glucocorticoid-induced apoptosis. Int Immunol 21(11):1269–1276. doi:10.1093/intimm/dxp093 PubMedCrossRef

76.

Lee SR, Kim HK, Youm JB, Dizon LA, Song IS, Jeong SH, Seo DY, Ko KS, Rhee BD, Kim N, Han J (2012) Non-genomic effect of glucocorticoids on cardiovascular system. Pflugers Arch 464(6):549–559. doi:10.1007/s00424-012-1155-2 PubMedCrossRef

77.

Mitre-Aguilar IB, Cabrera-Quintero AJ, Zentella-Dehesa A (2015) Genomic and non-genomic effects of glucocorticoids: implications for breast cancer. Int J Clin Exp Pathol 8(1):1–10PubMedPubMedCentral

78.

Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D (2000) Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med 6(6):703–706. doi:10.1038/76287 PubMedCrossRef

79.

Matias PM, Carrondo MA, Coelho R, Thomaz M, Zhao XY, Wegg A, Crusius K, Egner U, Donner P (2002) Structural basis for the glucocorticoid response in a mutant human androgen receptor [AR(ccr)] derived from an androgen-independent prostate cancer. J Med Chem 45(7):1439–1446PubMedCrossRef

80.

Chang CY, Walther PJ, McDonnell DP (2001) Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61(24):8712–8717PubMed

81.

Iguchi K, Hashimoto M, Kubota M, Yamashita S, Nakamura M, Usui S, Sugiyama T, Hirano K (2014) Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells. Oncol Lett 7(5):1665–1668. doi:10.3892/ol.2014.1936 PubMedPubMedCentral

82.

Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsuki T, Yamamoto T, Tanaka H (2002) Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 68(1):10–15PubMedCrossRef

83.

Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, Parker CC (2008) Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101(4):440–443. doi:10.1111/j.1464-410X.2007.07261.x PubMed

84.

Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A, Homma Y (2011) Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol 43(4):1081–1087. doi:10.1007/s11255-011-9922-0 PubMedCrossRef

85.

Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O’Brien N, McFaul S, Oliver T (2011) A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: immediate vs deferred Diethylstilbestrol. Br J Cancer 104(4):620–628. doi:10.1038/bjc.2011.7 PubMedPubMedCentralCrossRef

86.

Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C (2015) A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67(4):673–679. doi:10.1016/j.eururo.2014.10.004 PubMedCrossRef

87.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756–1764PubMed

88.

Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW, Aaronson N, de Prijck L, Collette L (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19(1):62–71PubMed

89.

Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L (2002) Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 168(6):2439–2443. doi:10.1097/01.ju.0000035648.32750.00 PubMedCrossRef

90.

Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, Van Erps P, Theodore C, Koriakine O, Oliver T, Lebwohl D, Debois M, Zurlo A, Collette L, Genitourinary Tract Group of the E (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68(1):2–9. doi:10.1159/000084201 PubMedCrossRef

91.

Fossa SD, Jacobsen AB, Ginman C, Jacobsen IN, Overn S, Iversen JR, Urnes T, Dahl AA, Veenstra M, Sandstad B (2007) Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study. Eur Urol 52(6):1691–1698. doi:10.1016/j.eururo.2007.01.104 PubMedCrossRef

92.

Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, Ferrero JM, Eymard JC, Falcon S, Calabro F, James N, Bodrogi I, Harper P, Wirth M, Berry W, Petrone ME, McKearn TJ, Noursalehi M, George M, Rozencweig M (2009) Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 27(32):5431–5438. doi:10.1200/jco.2008.20.1228 PubMedCrossRef

93.

Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS (2012) Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983–992. doi:10.1016/s1470-2045(12)70379-0 PubMedCrossRef

94.

Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C (2013) Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 14(12):1193–1199. doi:10.1016/s1470-2045(13)70424-8 PubMedCrossRef

95.

Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. New Engl J Med 368(2):138–148. doi:10.1056/NEJMoa1209096 PubMedCrossRef

96.

Michaelson MD, Oudard S, Ou YC, Sengelov L, Saad F, Houede N, Ostler P, Stenzl A, Daugaard G, Jones R, Laestadius F, Ullen A, Bahl A, Castellano D, Gschwend J, Maurina T, Chow Maneval E, Wang SL, Lechuga MJ, Paolini J, Chen I (2014) Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J Clin Oncol 32(2):76–82. doi:10.1200/jco.2012.48.5268 PubMedCrossRef

97.

Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K (2014) Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 65(5):875–883. doi:10.1016/j.eururo.2013.09.005 PubMedCrossRef

98.

Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F (2014) Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66(5):815–825. doi:10.1016/j.eururo.2014.02.056 PubMedPubMedCentralCrossRef

99.

Ryan CJ, Peng W, Kheoh T, Welkowsky E, Haqq CM, Chandler DW, Scher HI, Molina A (2014) Androgen dynamics and serum PSA in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis 17(2):192–198. doi:10.1038/pcan.2014.8 PubMedPubMedCentralCrossRef

100.

Sternberg CN, Castellano D, Daugaard G, Geczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ (2014) Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncol 15(11):1263–1268. doi:10.1016/s1470-2045(14)70417-6 PubMedCrossRef

101.

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R (2015) Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 33(7):723–731. doi:10.1200/jco.2014.56.5119 PubMedPubMedCentralCrossRef

102.

Montgomery B, Kheoh T, Molina A, Li J, Bellmunt J, Tran N, Loriot Y, Efstathiou E, Ryan CJ, Scher HI, de Bono JS (2015) Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301. Eur Urol 67(5):866–873. doi:10.1016/j.eururo.2014.06.042 PubMedCrossRef

103.

Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ (2015) Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol 33(12):1356–1363. doi:10.1200/jco.2014.55.3875 PubMedPubMedCentralCrossRef

104.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160. doi:10.1016/s1470-2045(14)71205-7 PubMedCrossRef

105.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 16(3):338–348. doi:10.1016/s1470-2045(15)70027-6 PubMedCrossRef

106.

Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE, Investigators C-A- (2015) Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152–160. doi:10.1016/S1470-2045(14)71205-7 PubMedCrossRef

107.

Green AK, Corty R, Wood WA, Meeneghan M, Reeder-Hayes KE, Basch E, Milowsky MI, Dusetzina SB (2015) Comparative effectiveness of mitoxantrone plus prednisone versus prednisone alone in metastatic castrate-resistant prostate cancer after docetaxel failure. Oncologist. doi:10.1634/theoncologist.2014-0432

108.

Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R, Investigators E-P (2015) Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 16(3):338–348. doi:10.1016/S1470-2045(15)70027-6 PubMedCrossRef

109.

Zhou T, Zeng SX, Ye DW, Wei Q, Zhang X, Huang YR, Ye ZQ, Yang Y, Zhang W, Tian Y, Zhou FJ, Jie J, Chen SP, Sun Y, Xie LP, Yao X, Na YQ, Sun YH (2015) A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer. PLoS ONE 10(1):e0117002. doi:10.1371/journal.pone.0117002 PubMedPubMedCentralCrossRef

110.

Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J, Parker C (2014) A Randomised Phase 2 Trial of Dexamethasone Versus Prednisolone in Castration-resistant Prostate Cancer. Eur Urol. doi:10.1016/j.eururo.2014.10.004 PubMed

111.

Holder SL, Drabick J, Zhu J, Joshi M (2015) Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer. Cancer Biol Ther 16(2):207–209. doi:10.1080/15384047.2014.1002687 PubMedPubMedCentralCrossRef

112.

Krishnan AV, Zhao XY, Swami S, Brive L, Peehl DM, Ely KR, Feldman D (2002) A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer. Endocrinology 143(5):1889–1900. doi:10.1210/endo.143.5.8778 PubMedCrossRef

113.

Langhoff E, Ladefoged J (1983) Relative immunosuppressive potency of various corticosteroids measured in vitro. Eur J Clin Pharmacol 25(4):459–462PubMedCrossRef

114.

Niraula S, Le LW, Tannock IF (2013) Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol 31(16):2029–2036. doi:10.1200/JCO.2012.46.5492 PubMedCrossRef

115.

De Santis M, Saad F (2016) Practical guidance on the role of corticosteroids in the treatment of metastatic castration-resistant prostate cancer. Urology 96:156–164. doi:10.1016/j.urology.2016.02.010 PubMedCrossRef

Titel: The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside
verfasst von: Jieping Hu
Qingke Chen
Publikationsdatum: 16.12.2016
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 3/2017
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1476-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2017

Measuring creatinine excretion and clearance for diagnosing and staging chronic kidney disease

Obesity, acute kidney injury and outcome of critical illness

Improving the diagnostic workup of hyponatremia in the setting of kidney disease: a continuing medical education (CME) initiative

Treatment of reno-ureteral colic by twelfth intercostal nerve block with lidocaine versus intramuscular diclofenac

Modification of the 2012 CKD-EPI equations for the elderly Chinese

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin